돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 420157생성일: 2026년 10월 25일

Methyl morpholine oxide → Tert-butyl 4-oxo-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)spiro[chroman-2,4'-piperidine]-1'-carboxylate

https://huagongshe.com/reaction/420157

반응식

참여 물질

역할이름HCID투입량
반응물Methyl morpholine oxideHCID 82029—
반응물Tert-butyl 4-hydroxy-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)spiro[chroman-2,4'-piperidine]-1'-carboxylateHCID 136136847—
촉매HCID 178419074HCID 178419074—
용매Acetonitrile tetrahydrofuranHCID 22177404—
생성물Tert-butyl 4-oxo-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)spiro[chroman-2,4'-piperidine]-1'-carboxylateHCID 136058068—

반응 단계

To a solution of 1.0 g of tert-butyl 4-hydroxy-6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)spiro[chroman-2,4′-piperidine]-1′-carboxylate in 40 ml of THF-CH3CN (1:1) at r.t. were added 2.0 g of MS 4A, 435 mg of NMO, and 88 mg of TPAP, and the reaction mixture was stirred at r.t. overnight. The mixture was filtered through a Celite pad, washed with CHCl3 and CHCl3-MeOH (9:1), and the filtrate was concentrated in reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of hexane-AcOEt (100/0-0/100) as eluent to give the intended compound as a colorless solid.

출처 및 근거

DOI10.6084/m9.figshare.5104873.v1
특허 번호US08093389B2
출처 데이터셋uspto-grants-2012_01
ORD IDord-0fe58e149f9b4e03a7baf5149d62f739
출처 메모uspto-grants-2012_01